This website is for UK Healthcare Professionals only

This promotional website is for UK healthcare professionals involved in the care of patients with ovarian cancer.

This promotional website is for UK healthcare professionals involved in the care of patients with ovarian cancer.

You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for ELAHERE. Adverse event reporting information is at the bottom of this page.

 
1. ELAHERE SmPC

UK-ELAH-260244. Date of Preparation: August 2026

You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for ELAHERE. Adverse event reporting information is at the bottom of this page.

1. ELAHERE SmPC

UK-ELAH-260244. Date of Preparation: August 2026

UK-ELAH-260246. Date of Preparation: August 2026

Folate receptor alpha in ovarian cancer: practical approaches, treatments, protocols and analytical challenges

Folate receptor alpha in ovarian cancer: practical approaches, treatments, protocols and analytical challenges

Ovarian cancer remains one of the most challenging gynaecological malignancies worldwide.1,2 Despite advances in first-line treatment, most patients with advanced disease will experience recurrence, and many will ultimately develop platinum-resistant ovarian cancer (PROC).3–6

An educational webinar organised and funded by AbbVie brought together leading oncology and pathology experts to discuss the evolving role of folate receptor alpha (FRα) in PROC. The session explored the clinical significance of FRα as a predictive biomarker,7 the emerging role of ELAHERE (mirvetuximab soravtansine),8 and practical considerations for implementing FRα testing into routine UK clinical practice.

With NICE recommending mirvetuximab soravtansine for eligible patients with FRα-positive PROC, in line with its licensed indication and in accordance with the commercial arrangement,9 this is an important time to revisit the key discussions and practical insights shared during the webinar.

Below, you can access a summary of the webinar alongside the on-demand video content to refresh your knowledge or catch up on the sessions you may have missed.

(20 mins)
FRα and the importance of timely diagnosis to improve outcomes in platinum-resistant ovarian cancer

(30 mins)
FRα Immunohistochemistry: What, how and when?

(20 mins)
Q&A session


Abbreviations

ADC, antibody-drug conjugate; BRCA, breast cancer susceptibility gene 1; CPD, continuing professional development; FFPE, formalin-fixed paraffin-embedded; FRα, folate receptor-alpha; HRD, homologous recombination deficiency; NICE, National Institute of Health and Care Excellence; PROC, platinum-resistant ovarian cancer; SmPC, summary of product characteristics.

References

  1. Hanker LC, et al. Ann Oncol. 2012;23(10):2605-2612.
  2. González-Martín A, et al. Ann Oncol. 2023;34(10):833-848.
  3. Ke Xu, et al. Expert Rev Clin Pharmacol. 2023;16(11):1141-1152.
  4. Giornelli GH. Springerplus. 2016;5(1):1197.
  5. Salani R, et al. Am J Obstet Gynecol. 2011;204(6):466-478.
  6. St Laurent J and Liu JF. J Clin Oncol. 2024;42(2):127-133.
  7. Zannoni GF, et al. Int J Mol Sci. 2025;26(11):5222.
  8. ELAHERE SmPC.
  9. NICE. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. TA1169. Available from: https://www.nice.org.uk/guidance/ta1169 [Accessed November 2026].
  10. Colombo N et al. Ann Oncol. 2019;30(5):672-705.
  11. Richardson DL, et al. JAMA Oncol. 2023;9(6):851-859.
  12. Gaillard S, et al. Gynecol Oncol. 2021;163(2):237-245.
  13. Pujade-Lauraine E, et al. J Clin Oncol. 2014;32(13):1302-1308.
  14. Poveda AM, et al. J Clin Oncol. 2015;33(32):3836-3838.
  15. Birrer MJ, et al. Oncologist. 2019;24(4):425-429.
  16. Scaranti M, et al. Nat Rev Clin Oncol. 2020;17(6):349-359.
  17. Köbel M, et al. Br J Cancer. 2014;111(12):2297-2307.
  18. Despierre E, et al. Gynecol Oncol. 2013;130(1):192-199.
  19. Rubinsak LA, et al. Appl Immunohistochem Mol Morphol. 2018;26(8):567-572.
  20. Ab O et al. Mol Cancer Ther. 2015;14(7):1605-1613.
  21. Moore K et al. Cancer. 2017;35(10):1112-1118.
  22. Fu Z et al. Sig Transduct Target Ther. 2022;7:93.
  23. Moore KN, et al. Ann Oncol. 2021;32:757-765.
  24. Moore KN, et al. N Engl J Med. 2023;389(23):2162-2174.
  25. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer V.4.2026. April 10, 2026 [Accessed November 2026].
  26. Zannoni GF, et al. Int J Mol Sci. 2025;26(11):5222.
  27. Martin LP, et al. Gynecol Oncol. 2017;147(2):402-407.
  28. VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay. Interpretation guide for epithelial ovarian, fallopian tube, or primary peritoneal cancer. VENTANA Medical Systems Inc/Roche Diagnostics International Inc; 2025.
  29. Based on speaker’s own experience and practice.
  30. Krivak T, et al. American Society of Clinical Oncology (ASCO) Annual Meeting. 2025. Poster 466.
  31. Cecere SC, et al. ESGO 2026. Oral presentation.

UK-ELAH-260249. Date of Preparation: November 2026

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

By clicking the link above, you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

NICE Guidance (TA1169)1

Mirvetuximab soravtansine can be used, within its marketing authorisation, as an option to treat folate receptor-alpha (FRα) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults after one to three lines of systemic treatment. Mirvetuximab soravtansine can only be used if the company provides it according to the commercial arrangement.1

NICE Guidance (TA1169)1

Mirvetuximab soravtansine can be used, within its marketing authorisation, as an option to treat folate receptor-alpha (FRα) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults after one to three lines of systemic treatment. Mirvetuximab soravtansine can only be used if the company provides it according to the commercial arrangement.1

SMC accepted as a treatment option2

ELAHERE (MIRVETUXIMAB SORAVTANSINE) IS ACCEPTED FOR USE WITHIN NHS SCOTLAND.

Advice: following a full submission assessed under the end of life and orphan equivalent medicine process:

Indication under review: as monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.2

SMC accepted as a treatment option2

ELAHERE (MIRVETUXIMAB SORAVTANSINE) IS ACCEPTED FOR USE WITHIN NHS SCOTLAND.

Advice: following a full submission assessed under the end of life and orphan equivalent medicine process:

Indication under review: as monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.2

1. NICE 2026. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer [TA1169] Published 24 June 2026. Available at: https://www.nice.org.uk/guidance/ta1169 (Accessed November 2026).

1. NICE 2026. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer [TA1169] Published 24 June 2026. Available at: https://www.nice.org.uk/guidance/ta1169 (Accessed November 2026).

*By clicking the link you will leave the AbbVie Pro website to an external website which is not under the control of AbbVie. AbbVie is not responsible for content of any such site or any further links from such site.
NICE, National Institute for Health and Care Excellence;  SMC, Scottish Medicines Consortium.

2. SMC 2026. Mirvetuximab soravtansine is accepted for use within NHSScotland as monotherapy for the treatment of adult patients with folate receptor- alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. Published 12 October 2026 https://scottishmedicines.org.uk/medicines-advice/mirvetuximab-soravtansine-elahere-fullsmc2892/ (Accessed November 2026).

2. SMC 2026. Mirvetuximab soravtansine is accepted for use within NHSScotland as monotherapy for the treatment of adult patients with folate receptor- alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. Published 12 October 2026 https://scottishmedicines.org.uk/medicines-advice/mirvetuximab-soravtansine-elahere-fullsmc2892/ (Accessed November 2026).

UK-ELAH-260245. Date of Preparation: November 2026

Faculty

Webinar date: Wednesday, 25th March 2026

FRα: a clinically relevant biomarker in ovarian cancer

FRα is a cell-surface receptor involved in folate transport.15 While expression in normal tissues is limited, FRα is frequently overexpressed in ovarian cancer, particularly high-grade serous ovarian cancer.16,17

Key observations include:

  • FRα is expressed in approximately 76% of high-grade serous ovarian cancers17
  • Expression is largely retained in recurrent and metastatic disease15,18,19
  • FRα expression has been observed to be maintained in some patients following chemotherapy exposure15,18,19
  • Limited expression in normal tissues makes it an ideal therapeutic target16

As antibody-drug conjugates (ADCs) continue to emerge across oncology, accurate biomarker assessment is becoming increasingly important to ensure the right patients receive the most appropriate treatment.

FRα is expressed in three-quarters of high-grade serous ovarian cancers and scarcely expressed in non-malignant ovarian tissues, making it an ideal therapeutic target15–19

Clinical evidence for FRα targeting

FORWARD I was the first international, randomised, open-label, phase 3 trial to assess the safety and clinical activity of ELAHERE compared with investigator’s choice chemotherapy (ICC) in adult patients with FRα-high, platinum-resistant highgrade serous epithelial ovarian cancer.23

The FORWARD I trial highlighted the importance of accurate FRα assessment to identify patients who will benefit most from targeted therapies. Subsequent analysis demonstrated that earlier scoring methodologies may have included patients with lower-than-intended FRα expression levels, potentially diluting treatment benefit. When samples were rescored using the current PS2+ methodology, improved outcomes emerged among patients with truly high FRα expression.23

Case study: the importance of timely FRα testing

Dr Angela George highlighted the journey of a 73-year-old woman with Stage IIIC high-grade serous ovarian cancer.

Following multiple lines of treatment and eventual platinum-resistant progression, archived tumour tissue was tested for FRα expression.

Results demonstrated:

≥75% of tumour cells showing moderate to strong membranous staining, meeting criteria for FRα positivity

The patient subsequently received ELAHERE and achieved:*

  • Partial response after three cycles
  • Near-complete response after six cycles
  • Manageable ocular toxicity controlled with steroid eye drops and ciclosporin.

*Clinician decision. Case study supplied by speaker. Prescribers should consult the ELAHERE Summary of Product Characteristics for further information on patient eligibility, including contraindications, special warnings and precautions.

Please note this is an individual patient and cases may vary. The eligibility decision described in the case is based on the information available at the time and the specified criteria met by the patient. Individual SmPCs may contain additional contraindications, precautions, or requirements that could affect eligibility. Clinicians should review the full prescribing information before initiating treatment.

MIRASOL: a landmark study

The Phase III MIRASOL study evaluated the safety and efficacy of ELAHERE versus ICC in patients with FRα-positive PROC.24

Importantly, MIRASOL demonstrated improvements in both PFS and overall survival (OS) with ELAHERE compared with standard chemotherapy.24

In addition, the incidence of serious adverse events (AEs) (52 participants [23.9%] in the ELAHERE group and in 68 (32.9%) in the chemotherapy group), grade ≥ 3 AEs (91 participants [41.7%] in the ELAHERE group and in 112 [54.1%] in the chemotherapy group), and treatment discontinuations due to AEs (n=20 [9.2%] vs. n=33 [15.9%]) was lower in the ELAHERE arm compared to ICC.24

MIRASOL primary endpoint – PFS24
mPFS was 5.62 months for patients treated with ELAHERE vs 3.98 months for patients treated with ICC (HR=0.65 [95% CI: 0.52–0.81]; P<0.0001]).
MIRASOL secondary endpoint – OS24
mOS was 16.46 months for patients treated with ELAHERE vs 12.75 months for patients treated with ICC (HR=0.67 [95% CI: 0.50–0.89]; P=0.0046).

Best practices for FRα testing: sample requirements

Appropriate specimens include:28

  • Formalin-fixed paraffin embedded (FFPE) tissue
  • Biopsies, resections, or excisions from primary or metastatic disease
  • Samples containing at least 100 viable tumour cells.

Resection vs biopsy
Evidence suggests resection specimens demonstrate higher FRα positivity rates than biopsies, likely reflecting tumour heterogeneity in FRα expression.30

Primary vs metastatic tissue
Both can be used successfully. Current evidence suggests sample location is less important than specimen quality.30

Cytology samples
Current companion diagnostic assays are not validated for cytology specimens. FFPE remains the preferred sample type.28

Practical considerations for pathology services

Successful implementation requires collaboration between oncology and pathology teams.25

Recommendations include:29

  • Minimising tissue wastage through coordinated sectioning
  • Preparing FRα sections alongside BRCA and HRD testing when possible
  • Sending additional slides to avoid repeat requests
  • Establishing efficient logistics and reporting pathways
  • Ensuring results are visible to both pathology and oncology teams.

Implementation tip:29

As the UK FRα testing network continues to expand, it is important to establish communication with the laboratory that will perform the test before submitting samples. Individual laboratories may have different requirements for specimen selection, preparation, packaging and request documentation. Checking local preferences in advance will help ensure samples are submitted correctly, minimise delays and support efficient integration of FRα testing into routine clinical practice.

Interpreting FRα staining

FRα scoring focuses on membrane staining intensity.28

A patient is considered FRα positive when:28

≥75% of viable tumour cells demonstrate moderate (2+) and/or strong (3+) membrane staining.28

For cases close to the threshold, second pathologist review is recommended to improve consistency and reduce variability.29